Foghorn Therapeutics Inc. (FHTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Foghorn Therapeutics reported revenue of $30.9M, up 36.8% from $22.6M the year before. Net income was -$74.3M (a -240.3% net margin), or -$1.18 per diluted share. Operating margin was -279.5%. Operating activities generated -$86.1M of cash, leaving -$86.1M of free cash flow. At fiscal year end, Foghorn Therapeutics held $198.1M in total assets against $306.6M in total liabilities, including $80.9M of cash and equivalents.
Open the full interactive Foghorn Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Foghorn Therapeutics Key Stats
| Share Price | $1.85 |
|---|---|
| Market Cap | $130.7M |
| Revenue YoY Growth | +36.8% |
| 52-Week Range | $1.85 – $7.07 |
| Shares Outstanding | 70.6 million (basic, 2026 Q2) |
Foghorn Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $430,000 | $1.3M | $19.2M | $34.2M | $22.6M | $30.9M |
| Operating Income | -$68.5M | -$100.7M | -$117.1M | -$107.9M | -$102.7M | -$86.4M |
| Pre-Tax Income | -$68.8M | -$101.3M | -$108.9M | -$94.2M | -$86.6M | -$74.3M |
| Income Tax | $0 | — | — | $4.2M | $0 | $0 |
| Net Income | -$68.8M | -$101.3M | -$108.9M | -$98.4M | -$86.6M | -$74.3M |
| Diluted EPS | -$6.23 | -$2.73 | -$2.62 | -$2.34 | -$1.58 | -$1.18 |
Foghorn Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $8.2M | $9.2M | $3.3M | $16.1M |
| Net Income | -$15.8M | -$21.7M | -$19.9M | -$7.2M |
| Diluted EPS | -$0.25 | -$0.34 | -$0.29 | -$0.10 |
Foghorn Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $92.8M | $101.1M | $52.2M | $80.3M | $55.5M | $80.9M |
| Current Assets | $190.7M | $459.6M | $351.4M | $240.2M | $249.6M | $163.2M |
| Total Assets | $255.6M | $519.8M | $404.9M | $285.9M | $284.0M | $198.1M |
| Current Liabilities | $18.8M | $48.7M | $55.2M | $58.4M | $67.0M | $59.7M |
| Total Long-Term Debt | $19.7M | — | — | — | — | — |
| Total Liabilities | $109.4M | $422.9M | $404.8M | $363.1M | $329.5M | $306.6M |
| Shareholders' Equity | $146.2M | $96.9M | $112,000 | -$77.2M | -$45.5M | -$108.5M |
Foghorn Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$31.3M | -$50.2M | $193.6M | -$118.1M | -$100.4M | -$86.1M |
| Cash From Investing | -$108.9M | $36.2M | -$244.3M | $144.4M | -$29.9M | $112.0M |
| Cash From Financing | $217.5M | $22.4M | $1.8M | $1.8M | $105.4M | $1.0M |
| Free Cash Flow | -$47.5M | -$53.6M | $192.4M | -$119.3M | -$101.3M | -$86.1M |
Figures from Foghorn Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Foghorn Therapeutics financials page for every line item.
Foghorn Therapeutics Company Profile
| Ticker | FHTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001822462 |
Frequently Asked Questions
What was Foghorn Therapeutics' revenue in fiscal 2025?
Foghorn Therapeutics (FHTX) reported revenue of $30.9M for fiscal 2025.
What is Foghorn Therapeutics' annual revenue history?
Foghorn Therapeutics' annual revenue by fiscal year: 2020: $430,000; 2021: $1.3M; 2022: $19.2M; 2023: $34.2M; 2024: $22.6M; 2025: $30.9M.
What was Foghorn Therapeutics' net income in fiscal 2025?
Foghorn Therapeutics reported net income of -$74.3M for fiscal 2025.
What was Foghorn Therapeutics' earnings per share (EPS) in fiscal 2025?
Foghorn Therapeutics' diluted EPS was -$1.18 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Foghorn Therapeutics generate in fiscal 2025?
Foghorn Therapeutics generated -$86.1M of free cash flow in fiscal 2025.
What was Foghorn Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Foghorn Therapeutics reported revenue of $16.1M.
How many shares of Foghorn Therapeutics are outstanding?
Foghorn Therapeutics reported a weighted average of 70.6 million basic shares outstanding in 2026 Q2.
What is Foghorn Therapeutics' market cap?
Based on its latest closing price, Foghorn Therapeutics (FHTX) has a market capitalization of about $130.7M.
When does Foghorn Therapeutics' fiscal year end?
Foghorn Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Foghorn Therapeutics headquartered?
Foghorn Therapeutics lists its business address in Cambridge, Massachusetts in its SEC filings.